Deals channel feed – Endpoints News

Deals channel feed

Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on the liver

4 years ago

Cytokinetics gets the Royalty treatment, snagging up to $450M to support closely watched heart programs

4 years ago

Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci

4 years ago

Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx

4 years ago

Planting another flag on Pfizer and Alnylam's turf, AstraZeneca grabs amyloidosis drug from the biotech that invented Aduhelm

4 years ago

Sanofi, Exscientia ink the next AI megadeal, signing terms on a $100M upfront pact with up to 15 drugs on the line

4 years ago

Novartis is 'all in' on siRNA, inking a new collaboration with Alnylam to develop alternative to liver transplants

4 years ago

Merck KGaA beefs up its mRNA work with a $780M buyout of a booming player

4 years ago

Amgen partners with Flagship's machine learning startup, promising up to $1.9B as Big Pharma ups bet on AI

4 years ago

Gary Glick puts Odyssey's $218M cash stack to use, acquiring machine learning outfit

4 years ago

You know AAV and LNP. What about PLV? Eli Lilly lines up new vehicle to deliver its genetic medicines

4 years ago

BioNTech and Pfizer announce $225M shingles vaccine project, offering mRNA challenger to GlaxoSmithKline's Shingrix

4 years ago

Biogen bets $60M upfront that a new antisense candidate from Ionis can one-up Spinraza

4 years ago

Sutro strikes a $40M China deal as it looks to push ahead of a crowded pack

4 years ago

Novartis unwraps $1.5B gene therapy buyout — beefing up arsenal against retinal diseases

4 years ago

Pouncing on next-gen I/O play, Sanofi acquires Amunix for $1B+ and picks up 'universal mask' tech

4 years ago

Merck KGaA snatches up Geneva biotech as repurposed chemotherapy mission strikes a 'Chord'

4 years ago

Tim Lu takes Senti and its gene circuit tech public in $296M deal riding on Omid Farokhzad's SPAC

4 years ago

Novartis turns to BeiGene again for the next big checkpoint target, paying $300M to jump into TIGIT race

4 years ago

Ipsen fronts $136M to bag Genfit's once-failed NASH drug, betting on its potential in rare liver condition

4 years ago

Horizon hits the gas pedal on renewed early-stage R&D, enlisting a Mitch Gold biotech in a $1.5B+ deal

4 years ago

Mesoblast shares tank after Novartis abandons a partnership for the biotech's potential Covid-19 treatment

4 years ago

As dust settles on the Arena buyout, Pfizer exec suggests company will pursue a more aggressive M&A strategy

4 years ago

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

4 years ago

First page Previous page 64 65 666768 69 70 Next page Last page